Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Naltrexone Methobromide
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Methylnaltrexone bromide is the active ingredient in Relistor®, an FDA-approved prescription medication indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic pain.
Brand Name : Relistor
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 01, 2022
Lead Product(s) : Naltrexone Methobromide
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : RCC-33
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : CNBX Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
CNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I/II (a) Clinical Trials
Details : Under the agreement, Purisys will support an IND filing process, including providing all necessary and related information concerning Chemistry Manufacturing and Controls (CMC) in the form of a comprehensive technical package to be presented to the FDA r...
Brand Name : RCC-33
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 04, 2021
Lead Product(s) : RCC-33
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : CNBX Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?